帕金
炎症体
致密部
神经退行性变
黑质
神经科学
帕金森病
细胞生物学
泛素连接酶
泛素
生物
多巴胺
化学
受体
医学
疾病
生物化学
多巴胺能
内科学
基因
作者
Nikhil Panicker,Tae‐In Kam,Hu Wang,Stewart Neifert,Shih-Ching Chou,Manoj Kumar,Saurav Brahmachari,Aanishaa Jhaldiyal,Jared T. Hinkle,Fatih Akkentli,Xiaobo Mao,Enquan Xu,Senthilkumar S. Karuppagounder,Eric T. Hsu,Sung Ung Kang,Olga Pletniková,Juan C. Troncoso,Valina L. Dawson,Ted M. Dawson
出处
期刊:Neuron
[Elsevier]
日期:2022-08-01
卷期号:110 (15): 2422-2437.e9
被引量:77
标识
DOI:10.1016/j.neuron.2022.05.009
摘要
Parkinson’s disease (PD) is mediated, in part, by intraneuronal accumulation of α-synuclein aggregates andsubsequent death of dopamine (DA) neurons in the substantia nigra pars compacta (SNpc). Microglial hyperactivation of the NOD-like receptor protein 3 (NLRP3) inflammasome has been well-documented in various neurodegenerative diseases, including PD. We show here that loss of parkin activity in mouse and human DA neurons results in spontaneous neuronal NLRP3 inflammasome assembly, leading to DA neuron death. Parkin normally inhibits inflammasome priming by ubiquitinating and targeting NLRP3 for proteasomal degradation. Loss of parkin activity also contributes to the assembly of an active NLRP3 inflammasome complex via mitochondrial-derived reactive oxygen species (mitoROS) generation through the accumulation of another parkin ubiquitination substrate, ZNF746/PARIS. Inhibition of neuronal NLRP3 inflammasome assembly prevents degeneration of DA neurons in familial and sporadic PD models. Strategies aimed at limiting neuronal NLRP3 inflammasome activation hold promise as a disease-modifying therapy for PD.
科研通智能强力驱动
Strongly Powered by AbleSci AI